Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.
For many, (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight off the global health scourge. Since then, it's been a bit of an off-radar stock, largely because it hasn't yet commercialized any other medications.
The lack of attention at the moment presents a fine opportunity to grab a deep-bargain stock, in the opinion of one analyst tracking Moderna. Here's why he thinks the biotech is poised for a monster comeback.
Piper Sandler's Edward Tenthoff is resolutely and emphatically bullish on Moderna's future. At the end of March, he reiterated both his overweight (read: buy) recommendation on the stock and his target of $214 per share price appreciation over the next 12 months or so. Tenthoff's confidence is apparent, as that level is more than double Moderna's most recent closing price of around $106.
Source Fool.com
Moderna Inc. Stock
We see a rather positive sentiment for Moderna Inc. with 16 Buy predictions and 2 Sell predictions.
With a target price of 125 € there is a slightly positive potential of 7.63% for Moderna Inc. compared to the current price of 116.14 €.
